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Abstract 26 
Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino acids and 27 
dipeptides was studied. Trp and Trp-containing dipeptides (Arg-Trp, Trp-Val, Val-Trp, Lys-Trp 28 
and Ile-Trp) inhibited XO. Three amino acids (Met, Leu and Trp) and eight dipeptides (Phe-Leu, 29 
Trp-Val, His-Leu, Glu-Lys, Ala-Leu, Val-Ala, Ser-Leu and Gly-Leu) inhibited DPP-IV. Trp and 30 
Trp-Val were multifunctional inhibitors of XO and DPP-IV. Lineweaver and Burk analysis 31 
showed that Trp was a non-competitive inhibitor of XO and a competitive inhibitor of DPP-IV. 32 
Molecular docking with Autodock Vina was used to better understand the interaction of the 33 
peptides with the active site of the enzyme. Because of the non-competitive inhibition observed, 34 
docking of Trp-Val to the secondary binding sites of XO and DPP-IV is required. Trp-Val was 35 
predicted to be intestinally neutral (between 25 and 75 % peptide remaining after 60 min 36 
simulated intestinal digestion). These results are of significance for the reduction of reactive 37 
oxygen species (ROS) and the increase of the half-life of incretins by food-derived peptides. 38 
 39 
Key words: dipeptidyl peptidase IV inhibitors, xanthine oxidase inhibitors, amino acids, 40 
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1. Introduction 43 
Various potential health promoting and disease risk reducing activities for milk proteins and 44 
milk-derived peptides have been reported (FitzGerald & Meisel, 2003; Pihlanto, 2006). Insulin 45 
secretion from pancreatic beta cells in the presence of glucose is influenced by incretins such as 46 
glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). 47 
Enzymatic degradation of these hormones by dipeptidyl peptidase IV (DDP-IV) activity can 48 
significantly reduce their level in vivo (Guasch, Ojeda, González-Abuín, Sala, Cereto-Massagué, 49 
Mulero, et al., 2012). It has been reported that peptides with 2-8 amino acid containing 50 
hydrophobic amino acid residues including Pro residues can inhibit DPP-IV. It has also been 51 
shown that milk derived peptides can inhibit DPP-IV activity (Lacroix & Li-Chan, 2012a, 2012b; 52 
Nongonierma & FitzGerald, 2013). Food protein derived DDP-IV inhibitory peptides may play a 53 
role in type 2 diabetes management by increasing the half-life of GIP and GLP-1 (Lacroix & Li-54 
Chan, 2012a).  55 
Cardiovascular and renal disease are complications associated with type 2 diabetes and insulin 56 
resistance syndrome. A link between hyperuricemia, the development of atherosclerosis, 57 
hypertension and insulin resistance has been proposed (Hayden & Tyagi, 2001). In type 2 58 
diabetes patients, the enzyme-based antioxidant systems involving superoxide dismutase, 59 
glutathione peroxidase and catalase may be depleted arising from increased oxidative stress 60 
(Hayden & Tyagi, 2001). An increase in the concentration of reactive oxygen species (ROS) in 61 
endothelial cells can result in endothelial injury. Supplementation of anti-oxidants through dietary 62 
intake has been proposed as a means to counteract oxidative stress. The in vitro anti-oxidative 63 
properties of milk proteins and peptides have been reviewed (Pihlanto, 2006; Power, Jakeman, & 64 
FitzGerald, 2012). An increase in the concentration of ROS can occur during the oxidation of 65 
xanthine to uric acid catalyzed by xanthine oxidase (XO). It has recently been shown that Trp-66 
containing dipeptides inhibit XO activity (Nongonierma & FitzGerald, 2012). 67 
Quantitative structure activity relationship (QSAR) and molecular docking approaches have 68 
  4 
been used to predict peptide binding to proteins (Pripp, 2007). While molecular docking 69 
strategies have been widely used as virtual screening tools for development of active substances 70 
in the pharmaceutical sector there appears to be limited use of this approach in the study of 71 
dietary compounds (Pripp, 2007). Some studies have used docking strategies to identify new 72 
peptide sequences with angiotensin converting enzyme (ACE) inhibitory properties or to better 73 
understand the interaction of peptides with ACE (Norris, Casey, FitzGerald, Shields, & Mooney, 74 
2012; Pripp, 2007). The peptide docking strategy developed by Norris et al. (2012) led to the 75 
discovery of two new dipeptide sequences (Asp-Trp and Trp-Pro) with potent in vitro ACE 76 
inhibitory properties. A good agreement between the Vina score and IC50 value was found for 77 
some dipeptides. 78 
No previous docking studies of peptides with XO have been conducted to our knowledge. 79 
Molecular docking of various flavonoids with XO has been carried out (Umamaheswari, 80 
Madeswaran, Asokkumar, Sivashanmugam, Subhadradevi, & Jagannath, 2012). Various potent 81 
DPP-IV inhibitors originating from natural products have recently been identified using a virtual 82 
screening procedure. A further increase in the DPP-IV inhibitory properties was achieved using 83 
derivatives of the most potent inhibitor (Guasch, et al., 2012). In a recent study, amaranth derived 84 
peptides with ≥ 13 amino acid residues have been docked with DPP-IV. The mechanism of 85 
inhibition of these relatively large peptides has been shown to involve blockage of the active 86 
DPP-IV dimer formation (Velarde-Salcedo, Barrera-Pacheco, Lara-González, Montero-Morán, 87 
Díaz-Gois, González de Mejia, et al., 2013). 88 
Given the link between diabetes and elevated ROS, it was decided to study the role if amino 89 
acids and dipeptides in controlling the activity of DPP-IV and XO. The aim of this study was 90 
therefore to determine the potential of amino acids and dipeptides to act as natural XO and DPP-91 
IV inhibitors. Protein-ligand docking (LIGPLOTs) and virtual screening with Autodock Vina 92 
were used to assess the XO and DPP-IV inhibitory properties of amino acids and dipeptides. 93 
Furthermore, the type of XO and DPP-IV inhibition mediated by the amino acids and dipeptides 94 
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was determined using Lineweaver and Burk kinetic analysis. 95 
2. Materials and methods 96 
2.1. Reagents 97 
Porcine DPP-IV (≥ 10 units/mg protein), Gly-Pro-para-nitroaniline (pNA), sodium phosphate 98 
monobasic, sodium phosphate dibasic, tris(hydroxymethyl)aminomethane (TRIS), 99 
ethylenediamine tretracetic acid (EDTA), hydroxylamine phosphate, xanthine, Allopurinol, 100 
bovine XO (0.1-0.4 units/mg protein) were obtained from Sigma Aldrich (Dublin, Ireland). The 101 
amino acids and synthetic peptides Trp, Met, Ala, Val, Cys, Leu, His, Ile, Arg, Thr, Glu, Tyr, 102 
Asp, Asn, Phe-Leu, His-Leu, Gly-Gln and Ile-Pro-Ile (Diprotin A) were obtained from Sigma-103 
Aldrich while Arg-Trp, Lys-Trp, Trp-Val, Val-Trp, Ile-Trp, Ser-Leu, Ala-Leu, Asp-Lys, Val-Ala, 104 
Glu-Lys, Gly-Leu and Ser-Phe were from Bachem (Bubendorf, Switzerland). Pro was from 105 
Merck (Darmstadt, Germany), Phe, Glu and Ser were from Sdn BHD (Pandamaran, Klang, 106 
Malaysia), Gly was from Fisher Scientific (Dublin, Ireland) and Lys was from SAFC Biosciences 107 
(Kansas, USA). 108 
2.2. XO inhibition assay 109 
The test samples (amino acids and dipeptides) were dispersed in HPLC grade water at 110 
concentrations ranging from 0.001 to 2.0 mg.mL
-1
. The XO inhibition assay was carried out as 111 
essentially described by Nongonierma & FitzGerald (2012). Briefly, test samples (50µL) were 112 
pipetted onto a 96 well microplate (Sarstedt, Dublin, Ireland) containing EDTA (final 113 
concentration 12.5µM), hydroxylamine phosphate (final concentration 25µM) and xanthine 114 
(final concentration 0.125 mM). The reaction was initiated by adding 50 µL of XO (0.1 U.mL
-1
). 115 
Each sample was analyzed in quadruplicate. The microplate was incubated at 37C for 30 min in 116 
a microplate reader (Biotek Synergy HT, Winoosky, VT, USA), absorbance of the uric acid 117 
formed was monitored at 290 nm. The XO IC50 values (concentration of active compound 118 
required to observe 50 % inhibition of XO) were determined by plotting the percentage inhibition 119 
as a function of the concentration of test compound. The mode of inhibition of the different 120 
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compounds was investigated using Lineweaver and Burk kinetic analysis by measuring the initial 121 
rate of the reaction at different xanthine concentrations between 0.0125 and 0.1250 mM without 122 
inhibitors and in the presence of inhibitors at their IC50 concentrations. Km and Vmax values 123 
were deducted from the Lineweaver and Burk double reciprocal plots. 124 
2.3. DPP-IV inhibition assay 125 
The test samples were dispersed in HPLC grade water at concentrations ranging from 0.01 to 126 
1.25 mg.mL
-1
. The DPP-IV inhibition assay was carried out as described by Lacroix & Li-Chan 127 
(2012a) and Nongonierma and FitzGerald (2013). Test samples (25µL) were pipetted onto a 96 128 
well microplate containing Gly-Pro-pNA (final concentration 0.200 mM). The negative control 129 
contained 100 mM Tris-HCl buffer pH 8.0 (25µL) and Gly-Pro-pNA. The reaction was initiated 130 
by the addition of DPP-IV (final concentration 0.0025 U.mL
-1
). Diprotin A was used as a positive 131 
control. Each sample was analysed in triplicate. The microplate was incubated at 37C for 60 min 132 
in a microplate reader, absorbance of the released pNA was monitored at 405 nm. The IC50 values 133 
for DPP-IV and the mode of inhibition of the different samples were determined as described in 134 
Nongonierma and FitzGerald (2013). The initial rate of reaction was measured at different Gly-135 
Pro-pNA concentrations between 0.200 and 0.600 mM without inhibitors and in the presence of 136 
inhibitors at their IC50 concentrations. 137 
2.4. Computational analysis 138 
AutoDock Vina (Trott & Olsen, 2010) was used to dock all 20 amino acids and 400 dipeptides 139 
to Protein Data Bank (PDB) structures 3BDJ, the crystal structure of bovine milk XO with a 140 
covalently bound oxipurinol inhibitor (Okamoto, Eger, Nishino, Pai, & Nishino, 2008), 1WCY, 141 
the crystal structure of human DPP-IV in complex with Diprotin A (Hiramatsu, Yamamoto, 142 
Kyono, Higashiyama, Fukushima, Shima, et al., 2005) and 1ORW, the crystal structure of porcine 143 
dipeptidyl peptidase IV (CD26) in complex with a peptidomimetic inhibitor (Engel, Hoffmann, Wagner, 144 
Wermann, Heiser, Kiefersauer, et al., 2003). Ten ligand inhibitors of XO were taken from their 145 
respective PDB files (Table 1) and docked to the PDB structure 3BDJ. Six ligand inhibitors of 146 
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DPP-IV were taken from their respective PDB files (Table 1) and docked to the PDB structures 147 
1WCY and 1ORW. The initial poses of the PDB-formatted structures of amino acids and 148 
dipeptides were generated using the Open Babel Package, version 2.1.1 (O'Boyle, Banck, James, 149 
Morley, Vandermeersch, & Hutchison, 2011). AutoDockTools (Morris, Huey, Lindstrom, 150 
Sanner, Belew, Goodsell, et al., 2009) was used to prepare the ligands and the two receptors, and 151 
to determine the ‘search space’. Amino acids, dipeptides and ligand inhibitors were then docked 152 
with the PDB structures giving a Vina score i.e., the predicted affinity of the molecule to bind to 153 
the PDB structure, calculated in kcal.mol
-1
. A more negative score indicates that a molecule 154 
(ligand) is more likely to dock with the structure (enzyme) and achieve more favorable 155 
interactions. LIGPLOTs were generated for the highest ranked Vina docking pose for each amino 156 
acid, dipeptide and inhibitor (using their PDB files as input and the best Vina docking poses) 157 
according to the protocol described by Wallace, Laskowski & Thornton (1995). Dipeptides were 158 
also assessed for their intestinal stability using an amino acid clustering model adopted from 159 
Foltz, van Buren, Klaffke & Duchateau (2009). This model rates dipeptides as ‘stable’ (> 75 % 160 
peptide remaining after 60 min simulated intestinal digestion- SID) ‘neutral’ (between 25 and 75 161 
% peptide remaining after 60 min SID) or ‘unstable’ (< 25 % peptide remaining after 60 min 162 
SID) with regard to small intestinal stability using correlations between the N- and C-terminal 163 
amino acids of dipeptides and the stability of the dipeptide in the intestine. Histograms and scatter 164 
plots were generated using the R package (2004). 165 
2.5. Statistical analysis 166 
For experimental data, means comparison was carried out with a one way ANOVA followed 167 
by a Tukey’s test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level P 168 
< 0.05. For the Lineweaver and Burk plots, experimental data was fitted by linear regression 169 
using SPSS. 170 
3. Results 171 
3.1. XO inhibitory properties of amino acids and dipeptides 172 
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The XO inhibitory properties of 20 amino acids and 15 dipeptides were studied. All six 173 
compounds (Trp, Arg-Trp, Trp-Val, Val-Trp, Lys-Trp and Ile-Trp) with XO inhibitory properties 174 
contained a Trp residue. Ile-Trp had the lowest IC50 value and Lys-Trp the highest IC50 value. 175 
The IC50 value of Ile-Trp was significantly lower (P< 0.05) compared to Trp, Trp-Val and Lys-176 
Trp IC50 values. In addition, the IC50 value of Lys-Trp was significantly higher (P< 0.05) 177 
compared to that of Arg-Trp and Val-Trp IC50 values (Table 2). 178 
The Lineweaver and Burk plots for XO inhibition by Arg-Trp, Lys-Trp and Ile-Trp are shown 179 
in Fig. 1. Vmax values were significantly different (P < 0.05) with and without inhibitors 180 
whereas the Km values were not significantly different (P ≥ 0.05). This suggests non-competitive 181 
inhibition by these dipeptides. Non-competitive XO inhibition by Trp, Val-Trp and Trp-Val has 182 
been previously been reported by Nongonierma & FitzGerald (2012). 183 
3.2. DPP-IV inhibitory properties of amino acids and dipeptides 184 
DPP-IV inhibition was observed with 3 amino acids (Met, Leu and Trp). The IC50 values for 185 
Met, Leu and Trp were 2381.51 ± 25.44, 3419.25 ± 55.68 and 4280.40 ± 48.03 µM, respectively 186 
(Table 2). With the exception of Phe-Leu and Trp-Val, the Vina score for Val-Trp (-7.0) was 187 
lower than that of the other dipeptides with DPP-IV inhibitory properties (Table 2). However, 188 
Val-Trp did not inhibit DPP-IV. Similarly, two other dipeptides with a Vina score ≤ -7.0 (Arg-189 
Trp and Lys-Trp) did not inhibit DPP-IV (Table 2). The Lineweaver and Burk plots for Met, Leu 190 
and Trp inhibition of DPP-IV are illustrated in Fig. 2. For Met (Fig. 2a), Leu (Fig. 2b) and Trp 191 
(Fig. 2c), the Vmax was not significantly different (P ≥ 0.05) with and without inhibitors, 192 
whereas Km values were significantly different (P < 0.05), suggesting a competitive type of 193 
inhibition. 194 
3.3. Molecular docking of XO and DPP-IV with amino acids and dipeptides and intestinal 195 
stability of dipeptides 196 
The frequency of distribution of the Vina scores for the amino acids, dipeptides and ligand 197 
inhibitors is illustrated on Fig. 3 for (a) bovine XO, (b) porcine DPP-IV and (c) human DPP-IV. 198 
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For XO, most of the compounds studied had Vina scores between -6.0 and -5.5 (Fig. 3a). By 199 
comparison, the Vina scores obtained for quercetin and mercaptopurine, compounds also known 200 
to inhibit XO, were -9.5 and -5.7, respectively when docked with 3BJD (Table 1). With the 201 
exception of Trp, Phe and Tyr which had values of -6.8, -7.0 and -7.4, respectively, the Vina 202 
scores for the amino acids were greater than -6.5 (Table 2). The Vina scores ranged between -4.6 203 
and -7.8 for the 15 dipeptides studied, while all Trp-containing dipeptides had Vina scores ≤ -7.0 204 
(Table 2). Differences in the interaction with XO were evident in the LIGPLOTs for Allopurinol, 205 
Trp, Val-Trp and Trp-Val (Fig. 4a, 4b, 4c and 4d). It was seen that docking between XO and Trp 206 
or Trp-containing dipeptides in the study herein involved interactions with at least with 6 207 
hydrophobic amino acid residues in XO. On the other hand, only 3 hydrophobic interactions were 208 
seen in the docking pose with Allopurinol (Fig. 4a). 209 
For interaction with DPP-IV, most compounds had a score between -7.5 and -6.5 (Fig. 3b and 210 
3c) while the Vina scores for the ligand inhibitors when docked with 1ORW ranged between -8.3 211 
and -5.2 (Table 1). Amino acids had Vina scores between -6.2 and -3.4. Of the 15 dipeptides 212 
studied, seven had Vina scores ≤ -6.5, five of which were Trp-containing dipeptides (Table 2). 213 
The distribution of Vina scores for the amino acids, dipeptides and ligand inhibitors were similar 214 
for porcine and human DPP-IV (data not shown). A linear relationship (slope = 1.03, R
2
 = 0.902) 215 
was observed between Vina scores for the different compounds studied with 1WCY (human 216 
DPP-IV) and 1ORW (porcine DPP-IV) (see supplementary Fig. i). DPP-IV LIGPLOTs for 217 
Diprotin A, Trp, Val-Trp and Trp-Val show that hydrophobic interactions and hydrogen bonds 218 
may be involved in the binding process (Fig. 4e, 4f, 4g and 4h). 219 
The predicted intestinal stability analysis of the 15 dipeptides was carried out according to 220 
Foltz et al. (2009). Five peptides (Ser-Phe, Glu-Lys, Gly-Gln, Asp-Lys and Gly-Leu) were 221 
predicted to be stable, one (Trp-Val) neutral and nine (Arg-Trp, Phe-Leu, Lys-Trp, Val-Trp, His-222 
Leu, Ile-Trp, Ala-Leu, Val-Ala and Ser-Leu) unstable (Table 2). Of the 15 dipeptides tested, the 223 
dipeptide with the lowest XO and DPP-IV Vina score and predicted to be intestinally stable was 224 
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Ser-Phe. With the exception of Trp-Val, which was neutral, all Trp-containing dipeptides were 225 
predicted to have a low intestinal stability (Table 2). 226 
4. Discussion 227 
Arg-Trp can in theory be released by gastro-intestinal enzyme activities from lactoferrin (LF), 228 
Lys-Trp from β-lactoglobulin and Ile-Trp from LF and -lactalbumin according to in silico 229 
analysis with the Peptide Cutter Program (ExPaSy, 2011). All other dipeptides with the exception 230 
of Phe-Leu, His-Leu, Trp-Val and Gly-Gln, can be released from various milk protein substrates 231 
by the action of gastro-intestinal enzyme activities (Nongonierma & FitzGerald, 2012). Trp, Trp-232 
Val and Val-Trp have previously been identified as non-competitive inhibitors of XO. It was 233 
shown that the N or C-terminal location of Trp did not affect the ability of Trp-containing 234 
dipeptides to inhibit XO as there was no significant difference (P ≥ 0.05) for the IC50 values for 235 
both peptides (Nongonierma & FitzGerald, 2012). Three other Trp-containing dipeptides, Ile-Trp, 236 
Lys-Trp and Arg-Trp, were shown herein to be non-competitive inhibitors of XO (Table 2, Fig. 237 
1). The results herein also show that apart from Trp, none of the other amino acids could inhibit 238 
XO (Table 2). The inhibitory properties of Trp have been attributed to their similarity with drug 239 
inhibitors of XO which have xanthine-like structures (e.g. Allopurinol) (Nongonierma & 240 
FitzGerald, 2012). To our knowledge, no previous studies appear to report on the molecular 241 
docking of amino acids and dipeptides to the active site of XO. Molecular docking of ligand 242 
inhibitors, amino acids and dipeptides was performed in order to better understand the molecular 243 
mechanism of XO inhibition by amino acids and dipeptides. Trp, Tyr and Phe contain C6 244 
(phenyl/phenol) structures. However, Tyr and Phe do not inhibit XO, presumably due to the fact 245 
that they do not possess xanthine-like structural features. The Vina score for Trp interaction with 246 
XO was -6.8, indicative of a good interaction with the active site of XO (Table 2). Surprisingly, 247 
the Vina score for Phe and Tyr were -7.0 and -7.4, respectively. The reason(s) for the apparently 248 
good fit of those amino acids in the active site requires further investigation. A non-competitive 249 
inhibition of XO was observed for Trp and the Trp-containing dipeptides (Fig. 1), suggesting that 250 
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these compounds may not interact directly with the active site of XO. The exact nature of the 251 
mode of inhibition with Trp and Trp-containing dipeptides requires further studies. While 252 
different polyphenolic compounds have also been reported as non-competitive inhibitors of XO 253 
their actual mode of inhibition has still not been fully elucidated (Spanou, Veskoukis, Kerasioti, 254 
Kontou, Angelis, Aligiannis, et al., 2012). 255 
Most of the peptides with DPP-IV inhibitory properties described in the literature to date 256 
contain between two to eight amino acid residues (Lacroix & Li-Chan, 2012b). However, the 257 
results herein show that smaller molecular mass components such as amino acids (Trp, Met and 258 
Leu) are also able to inhibit DPP-IV (Table 2). The eight dipeptides inhibitors, Trp-Val, Ala-Leu, 259 
Glu-Lys, Gly-Leu, Ser-Leu, Phe-Leu, His-Leu and Val-Ala, have previously been identified as 260 
DPP-IV inhibitors (Nongonierma & FitzGerald, 2013). Val-Ala has been identified in previous 261 
studies as an inhibitor of DPP-IV. This peptide occurs in different milk proteins including -, - 262 
and -casein, -lactoglobulin and LF (Lacroix & Li-Chan, 2012b). The IC50 values found for the 263 
dipeptides studied herein are of the same order as the values reported in the literature for other 264 
DPP-IV inhibitory peptides. An IC50 of 46 µM was reported for Leu-Pro-Gln-Asn-Ile-Pro-Pro-265 
Leu (-casein(f70-77)) while other -casein derived peptides had IC50 values between 110 and 266 
1500 µM (Uenishi, Kabuki, Seto, Serizawa, & Nakajima, 2012). The most potent DPP-IV 267 
inhibitory dipeptide herein was Trp-Val (65.69 ± 2.95 µM). However, the reverse peptide Val-268 
Trp did not inhibit DPP-IV (Nongonierma & FitzGerald, 2013). A similar observation has 269 
recently been reported in the case of Ile-Pro (IC50 0.41 ± 0.07 µM) where its reverse peptide, Pro-270 
Ile, did not inhibit DPP-IV (Hatanaka, Inoue, Arima, Kumagai, Usuki, Kawakami, et al., 2012). 271 
The hydrolytic specificity of DPP-IV shows that the most effective substrates possess a Pro 272 
residue in the P1 position (Engel, Hoffmann, Manhart, Heiser, Chambre, Huber, et al., 2006; 273 
Kühn-Wache, Bär, Hoffmann, Wolf, Rahfeld, & Demuth, 2011). Other peptides having Ala, Gly 274 
or Ser residues in the P1 position are also substrates of DPP-IV (Kühn-Wache, Bär, Hoffmann, 275 
Wolf, Rahfeld, & Demuth, 2011). The enzymatic mechanism of DPP-IV involves recognition of 276 
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a charged N-terminus by a Glu-Glu motif and interaction of the amino acid in position P1 of the 277 
substrate with an hydrophobic pocket in the enzyme (Engel, et al., 2006; Guasch, et al., 2012; 278 
Kühn-Wache, Bär, Hoffmann, Wolf, Rahfeld, & Demuth, 2011). 279 
Different DPP-IV dipeptide inhibitors with a Pro residue at the C terminus have been 280 
identified (Hatanaka, et al., 2012). However, other dipeptides which do not contain a Pro residue 281 
are also able to inhibit DPP-IV (Lacroix & Li-Chan, 2012b). When Trp was positioned at the C 282 
terminus (Val-Trp, Ile-Trp, Arg-Trp, and Lys-Trp), no DPP-IV inhibition was seen in contrast 283 
with the dipeptide Trp-Val. Another peptide with a Trp residue at the N terminus, Trp-Pro, has 284 
been reported as a DPP-IV inhibitor (Hatanaka, et al., 2012; Lacroix & Li-Chan, 2012b). 285 
Inhibition of DDP-IV may correlate with Trp positioned at the N terminus of dipeptides. High 286 
DPP-IV inhibition seen with a Trp containing dipeptide has been associated with the fact that the 287 
indole group from Trp may interact with the phenyl group of the Ala-Pro-pNA substrate, 288 
resulting in a fixation of the substrate to Trp and an apparent higher DPP-IV inhibition (Lorey, 289 
Stöckel-Maschek, Faust, Brandt, Stiebitz, Gorrell, et al., 2003). Our data rules out this possibility 290 
as no DPP-IV inhibition was seen with the other Trp-containing dipeptides (Val-Trp, Ile-Trp, 291 
Arg-Trp, and Lys-Trp). It has been shown that some DPP-IV peptide inhibitors such as Diprotin 292 
A (Ile-Pro-Ile) and Diprotin B (Val-Pro-Leu) behave like DPP-IV substrates. The dipeptides Ile-293 
Pro and Val-Pro released by the hydrolytic activity of DPP-IV on Diprotin A and B, respectively, 294 
are also inhibitors of DPP-IV (Hatanaka, et al., 2012). It is interesting to note that Ile-Pro, which 295 
is released following the hydrolysis of Diprotin A by DPP-IV, has a lower Vina score (-6.6) than 296 
that of Diprotin A (-5.9). This may suggest that Ile-Pro is a more potent inhibitor than Diprotin A. 297 
Similarly, it has been suggested that some food-derived peptides may present structural analogies 298 
with DPP-IV substrates and behave as substrates for this enzyme (Lacroix & Li-Chan, 2012a). In 299 
such cases, the peptides may compete with the synthetic substrate used in the DPP-IV assay (Gly-300 
Pro-pNA) for binding to the active site. This would result in a reduction in the release of pNA, 301 
leading to a false positive in the DPP-IV assay. However, it is unlikely that amino acids and 302 
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dipeptides studied herein could act as substrates for DPP-IV as substrates for this enzyme should 303 
possess more than 2 amino acid residues (Engel, et al., 2006). Most of the DPP-IV inhibitors 304 
studied herein were competitive inhibitors with the exception of Trp-Val which was non-305 
competitive (Table 2). An hydrophobic pocket at the active site of DPP-IV, composed of Tyr-306 
666, Tyr-662, Val-711, Val-656, and Trp-659, has previously been described (Engel, et al., 307 
2003). The LIGPLOTs of Diprotin A and Trp, two competitive inhibitors of DPP-IV, show that 308 
these inhibitors interact with the hydrophobic pocket of the active site involving Tyr-666 and 309 
Tyr-662 residues of DPP-IV (Fig. 4e and 4f). For the other competitive inhibitors of DPP-IV 310 
(Leu, Phe-Leu, His-Leu, Glu-Lys, Ala-Leu, Val-Ala, Ser-Leu and Gly-Leu), the LIGPLOTS 311 
(data not shown) revealed hydrophobic interactions with Tyr-666 and also in some cases with 312 
Tyr-662 (Phe-Leu, His-Leu, Glu-Lys and Val-Ala). Met was the only inhibitor which could not 313 
interact with any of the previously identified amino acid residues of the hydrophobic pocket of 314 
DPP-IV. For the other amino acids and dipeptides which were competitive inhibitors of DPP-IV, 315 
the Vina scores for DPP-IV did not seem to be in agreement with their experimentally determined 316 
IC50 value. The Pepsite2 tool (Trabuco, Lise, Petsalaki, & Russell, 2012) was used to determine 317 
the site of interaction of Trp-Val with DPP-IV. This analysis indicated a binding site for Trp-Val 318 
which was located near the active site of DPP-IV (see supplementary Fig. ii). Trp-Val interacts 319 
with DPP-IV near its active site yielding an inhibition which does not affect the affinity of 320 
binding (Km) for the substrate. Similar results have been reported for DPP-IV inhibitory peptides 321 
derived from the N terminus of the human immunodeficiency virus-1 (HIV) transactivator Tat, 322 
which can bind to a secondary site located close to the active site of DPP-IV. Binding of the 323 
inhibitors to the secondary site of DPP-IV resulted in a non-competitive inhibition (Lorey, et al., 324 
2003). Docking of peptides ≥ 13 amino acids derived from the tryptic digestion of amaranth has 325 
been carried out. The amaranth 11S globulin peptide f(1-13) was shown to interact with the 326 
cavity of DPP-IV, thereby blocking access of the substrate. Three peptides > 13 amino acids 327 
showed a mode of inhibition which did not involve the active site of DPP-IV. These large 328 
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peptides were shown to prevent the formation of the dimeric active form of DPP-IV, resulting in 329 
an inhibition of the enzyme (Velarde-Salcedo, et al., 2013). Interestingly, Trp and Trp-Val 330 
present a dual bioactivity, inhibiting both DPP-IV and XO. Trp-Val was shown to be a non-331 
competitive inhibitor of XO and DPP-IV, suggesting a binding outside the active site of the 332 
enzyme. In this instance, docking of Trp-Val to the active site cannot be utilized to determine 333 
interaction of the peptides with XO or DPP-IV. More knowledge is needed in terms of the 334 
structure of the secondary binding site of XO and DPP-IV in order to dock the non-competitive 335 
inhibitors to this site. 336 
Prediction of the intestinal stability indicates that most dipeptides were unstable (Table 2). It 337 
has been noted by Foltz et al. (2009) that the low intestinal stability of Trp-containing dipeptides 338 
could be detrimental to their bioactivity (ACE inhibitory properties). However Trp, and the Trp-339 
containing dipeptides (Arg-Trp, Trp-Val, Val-Trp, Lys-Trp and Ile-Trp) were able to inhibit XO. 340 
Therefore, it could be hypothesised that bioactivity may be retained even following hydrolysis of 341 
the dipeptides Arg-Trp, Trp-Val, Val-Trp, Lys-Trp and Ile-Trp by intestinal peptidases. 342 
Simulated intestinal digestion of a gastric LF hydrolysate was performed and the XO inhibitory 343 
properties of the subsequent hydrolysate were not impaired. This suggests that Trp and Trp-344 
containing components from this LF hydrolysate were still bioactive (Nongonierma & 345 
FitzGerald, 2012). It has been shown that LF hydrolysates which contain Trp and Trp-containing 346 
dipeptides could inhibit XO. A consequence of Trp-containing dipeptide cleavage by intestinal 347 
enzymes may be reduced bioavailability of Trp compared to the dipeptide. It has been shown that 348 
dipeptide uptake in vivo is more efficient than that for free amino acids (Adibi & Morse, 1971). 349 
In order to interact with XO, an inhibitor should cross the gut barrier and survive serum peptidase 350 
activity in order to reach locations containing XO (i.e. plasma, liver, gut, lung, kidney, brain and 351 
heart). However as hydrophobic peptides have been associated with a high intestinal trans-352 
epithelial permeation, Trp and Trp-containing dipeptides may be good candidates for XO 353 
inhibition as suggested elsewhere (Nongonierma & FitzGerald, 2012).  354 
  15 
In the case of DPP-IV, Trp-Val and Trp were also inhibitors. However, the IC50 of Trp was 355 
more than 60 times higher than that of Trp-Val, suggesting that hydrolysis of Trp-Val would 356 
result in a significant reduction in the overall DPP-IV inhibitory properties. The simulated 357 
gastrointestinal digestion (SGID) of DPP-IV inhibitory peptides from rice bran has been studied 358 
(Huang, Jao, Ho, & Hsu, 2012). Different effects of SGID on the bioactivity of the peptides were 359 
seen, showing no effect or an increase in the DPP-IV inhibition depending on the peptide 360 
sequence (Huang, Jao, Ho, & Hsu, 2012). In another study, SGID of amaranth glutelin resulted in 361 
an increase in DPP-IV inhibitory properties compared to raw amaranth flour (Velarde-Salcedo, et 362 
al., 2013). The fact that some amino acids behave as DPP-IV inhibitors suggests that release of 363 
these amino acid residues following cleavage of the dipeptides may affect the overall inhibitory 364 
activity. For example, not all Trp-containing dipeptides (i.e. Arg-Trp, Lys-Trp, Val-Trp and Ile-365 
Trp) inhibited DPP-IV in contrast with Trp. Intestinal instability of these dipeptides could 366 
increase DPP-IV inhibitory activity following the release of Trp. In the case of Leu-containing 367 
dipeptides (i.e. Phe-Leu, Ala-Leu, Ser-Leu and Gly-Leu), cleavage of the dipeptides will result in 368 
a decrease in the potency of the sample as the IC50 value for Leu is between 1.3 and 23.9 times 369 
greater than that of the dipeptides. Based on the absence of DPP-IV inhibition with Val and Ala, 370 
it is predicted that cleavage of Val-Ala, which is intestinally unstable, would result in a loss in 371 
DPP-IV inhibitory activity. 372 
A natural avenue for the prevention of type 2 diabetes may involve the incorporation of 373 
peptides in the diet of prediabetics or type 2 diabetic subjects. This study has demonstrated the 374 
possibility of targeting inhibition of XO and DPP-IV with amino acids and dipeptides as a means 375 
to reduce the generation of ROS and to enhance the half-life of incretins. Multi-functional foods 376 
containing amino acids and bioactive peptides may have potential in targeting different 377 
bioactivities. Further evaluation of Trp-Val is needed to verify its bioavailability and potential 378 
health benefits in vivo. 379 
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Conclusion 380 
Due to the non-competitive XO and DPP-IV inhibition seen with Trp-Val, there appears to be 381 
some limitations in the use of Vina scores determined by docking to the active sites of XO and 382 
DPP-IV. There is a lack of detailed information in the literature in terms of XO and DPP-IV 383 
inhibition by amino acids and dipeptides. Generation of additional experimental data for XO and 384 
DPP-IV inhibition with various dipeptides would be useful to validate bioinformatics based 385 
models for the discovery of new dipeptides sequences which act as inhibitors of these enzymes. 386 
This may lead to the identification of food-derived bioactive peptides which may be formulated 387 
into functional foods. 388 
389 
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Table 1 Summary details of the protein database bank (PDB) structures and associated Vina scores of xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) complexed with different 495 
ligands. 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
*Vina scores of the ligand provided with the structure back to the structure of bovine XO with a covalently bound oxipurinol inhibitor (3BJD) and porcine DPP-IV with a 511 
peptidomimetic inhibitor (1ORW). 512 
513 
Protein database 
identification code 
Description Vina 
score* 
 Xanthine oxidase (XO)  
3BDJ Crystal structure of bovine milk xanthine dehydrogenase with a covalently bound oxipurinol inhibitor -7.5 
1N5X Xanthine dehydrogenase from bovine milk with inhibitor TEI-6720 bound -8.2 
1V97 Crystal structure of bovine milk xanthine dehydrogenase FYX-051 bound form -8.5 
3AM9 Complex of bovine xanthine dehydrogenase and trihydroxy FYX-051 -9.1 
3ETR Crystal structure of xanthine oxidase in complex with lumazine -7.7 
3NRZ Crystal structure of bovine xanthine oxidase in complex with hypoxanthine -6.7 
3NS1 Crystal structure of bovine xanthine oxidase in complex with 6-mercaptopurine -5.7 
3NVW Crystal structure of bovine xanthine oxidase in complex with guanine -7.1 
3NVY Crystal structure of bovine xanthine oxidase in complex with quercetin -9.5 
3NVZ Crystal structure of bovine xanthine oxidase in complex with indole-3-aldehyde -7.7 
   
 Dipeptidyl peptidase (DPP-IV)  
1ORW Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a peptidomimetic inhibitor -5.9 
1WCY Crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with Diprotin A -6.2 
2AJ8 Porcine dipeptidyl peptidase IV (CD26) in complex with 7-benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-
purine-2,6-dione (BDPX) 
-7.8 
2AJC Porcine dipeptidyl peptidase IV (CD26) in complex with 4-(2-aminoethyl)-benzene sulphonyl fluoride (AEBSF) -5.2 
2BUA Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a low molecular weight inhibitor -5.6 
2BUC Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a tetrahydroisoquinoline inhibitor -8.3 
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Table 2 Summary of the Vina score, test compound concentration inducing 50 % inhibition (IC50) of xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) along with inhibition type 514 
for the dipeptides and amino acids with predicted intestinal stability of the dipeptides. IC50 values are mean ± confidence interval. 515 
 516 
Compound 
type 
Sequence Predicted 
stability
#
 
Xanthine oxidase  Dipeptidyl peptidase IV 
 
Vina score 
3BDJ
†
 
IC50 XO 
bovine(µM)
‡
 
Type of 
inhibition
*
 
 Vina score 
1ORW
§
  
IC50 DPP-IV 
porcine (µM)
# #
 
Type of 
inhibition
**
 
Dipeptide RW unstable -7.8 1136.9 ± 94.7
b,c
 non-competitive  -7.5 - - 
 FL unstable -7.7 - -  -7.6 399.58 ± 10.81
d
 competitive 
 KW unstable -7.2 1450.9 ± 183.0
d
 non-competitive   -7.2 - - 
 WV neutral -7.2 1301.7 ± 336.7
c,d
 non-competitive  -8.1 65.69 ± 2.95
b
 non-competitive 
 VW unstable -7.0 1195.7 ± 131.5
b,c
 non-competitive  -7.6 - - 
 SF stable -6.9 - -  -7.0 - - 
 HL unstable -6.5 - -  -6.7 143.19 ± 0.35
c
 competitive 
 IW unstable -6.2 1046.6 ± 67.0
b
 non-competitive   -7.7 - - 
 EK stable -5.9 - -  -6.3 3216.75 ± 2.12
h
 competitive 
 GQ stable -5.6 - -  -5.8 - - 
 DK stable -5.4 - -  -6.4 - - 
 AL unstable -4.9 - -  -5.7 882.13 ± 68.66
e
 competitive 
 VA unstable -5.7 - -  -5.4 168.24 ± 7.96
c
 competitive 
 SL unstable -4.8 - -  -5.7 2517.08 ± 36.33
f
 competitive 
 GL stable -4.6 - -  -5.7 2615.03 ± 612.80
g
 competitive 
          
Amino acid W na -6.8 1259.8 ± 84.5
c,d
 non-competitive  -6.2 4280.40 ± 48.03
h
 competitive 
 M na -4.1 - -  -4.0 2381.51 ± 25.44
f
 competitive 
 L na -5.0 - -  -4.3 3419.25 ± 55.68
h
 competitive 
 V na -5.3 - -  -4.2 - - 
 A na -4.6 - -  -3.7 - - 
 C na -4.5 - -  -3.7 - - 
 D na -5.0 - -  -4.8 - - 
 E na -5.6 - -  -5.1 - - 
 F na -7.0 - -  -5.5 - - 
 G na -3.9 - -  -3.4 - - 
 H na -5.3 - -  -4.8 - - 
 I na -4.1 - -  -4.7 - - 
  25 
 K na -6.0 - -  -4.4 - - 
 N na -5.0 - -  -4.6 - - 
 P na -4.2 - -  -4.5 - - 
 Q na -5.4 - -  -5.3 - - 
 R na -5.8 - -  -4.7 - - 
 S na -4.8 - -  -3.9 - - 
 T na -5.1 - -  -4.8 - - 
 Y na -7.4 - -  -5.7 - - 
          
Inhibitor Allopurinol na -7.3 5.5 ± 0.1
a
 competitive  na na na 
  IPI  na na na na  -5.9 4.23 ± 0.08
a
 competitive 
na: not applicable 517 
#
Predicted stability was determined according to Foltz et al. (2009). 518 
†
Crystal structure of bovine milk xanthine dehydrogenase with a covalently bound oxipurinol inhibitor 519 
‡
 Values represent mean IC50 values ± confidence interval (P = 0.05) for quadruplicate determination (n=4). Values with different superscript letters are significantly different 520 
(P < 0.05). For XO, IC50 values of W, VW and WV were taken from Nongonierma & FitzGerald (2012). 521 
*Type of inhibition determined using Lineweaver and Burk plots as described in Nongonierma & FitzGerald (2012) 522 
§
Crystal structure of porcine DPP-IV in complex with a peptidomimetic inhibitor 523 
**Type of inhibition determined using Lineweaver and Burk plots as described in Nongonierma & FitzGerald (2013) 524 
##
Values represent mean IC50 values ± confidence interval (P = 0.05) for triplicate determination (n=3). Values with different superscript letters are significantly different (P < 525 
0.05). IC50 values for the dipeptides were taken from Nongonierma & FitzGerald (2013) 526 
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Figure captions 527 
 528 
Fig. 1. Lineweaver and Burk plots for xanthine oxidase (XO) inhibition with Arg-Trp (a), Lys-Trp (b) 529 
and Ile-Trp (c). Each data point is the average of 6 values. 530 
 531 
Fig. 2. Lineweaver and Burk plots for dipeptidyl peptidase IV (DPP-IV) with Met (a), Leu (b) and Trp 532 
(c). Each data point is the average of 6 values. 533 
 534 
Fig. 3. Frequency of distribution of Vina scores for predicted binding of the 20 amino-acids, 400 possible 535 
dipeptides and ligands to xanthine oxidase (XO) and dipeptidyl peptidase IV (DDP-IV). Bovine XO (a), 536 
porcine DDP-IV (b) and human DDP-IV (c). 537 
 538 
Fig. 4. LIGPLOT profiles of the crystal structure of bovine milk xanthine oxidase (XO) with Allopurinol 539 
inhibitor (a), Trp (b), Val-Trp (c) and Trp-Val (d) and LIGPLOTs of the crystal structure of human 540 
dipeptidyl peptidase IV (DPP-IV) complex with Diprotin A (e), Trp (f), Val-Trp (g) and Trp-Val (h) 541 
 542 
 543 
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Fig. 4 616 
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Supplementary data 617 
 618 
 619 
 620 
 621 
Fig. i Correlation between the prediction of binding of the 20 amino-acids, 400 possible dipeptides to 622 
dipeptidyl peptidase IV (DPP-IV) binding site from porcine (1ORW) and human origin (1CWY). 623 
 624 
 625 
626 
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 627 
 628 
 629 
 630 
Fig. ii Dipeptidyl peptidase IV (DPP-IV) 1WCY structure with potential location for the dipeptide Trp-Val 631 
close to the active site, as defined by Pepsite2 (Trabuco, Lise, Petsalaki, & Russell, 2012) (P=0.0037) 632 
suggesting that binding is most likely to occur near the active site. 633 
 634 
